2022 Measure # 443 Non-Recommended Cervical Cancer Screening in Adolescent Females

Measure Type High Priority Measure? Collection Type(s)
Process yes MIPS CQM

Measure Description

The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer

Stay up to date with the latest news regarding MACRA and MIPS.

The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.


This measure is to be submitted once per performance period for female patients seen during the performance period. There is no diagnosis associated with this measure. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on services provided and the measure-specific denominator coding.

NOTE: Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.

Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.


Adolescent females 16-20 years of age with a visit during the measurement period

Denominator Criteria (Eligible Cases):

Patients aged 16-20 years of age on date of encounter


Patient encounter during the performance period (CPT or HCPCS): 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, G0402, G0438, G0439



A history of cervical cancer, HIV, or immunodeficiency any time during the patient’s history through the end of the measurement period: B20, B97.35, C53.0, C53.1, C53.8, C53.9, D06.0, D06.1, D06.7, D06.9, Z85.41, D80.0, D80.1, D80.2, D80.3, D80.4, D80.5, D80.6, D80.7, D80.8, D80.9, D81.0, D81.1, D81.2, D81.4, D81.6, D81.7, D81.89, D81.9, D82.0, D82.1, D82.2, D82.3, D82.4, D82.8, D82.9, D83.0, D83.1, D83.2, D83.8, D83.9, D84.0, D84.1, D84.8, D84.9, D89.3, D89.810, D89.811, D89.812, D89.813, D89.82, D89.89, D89.9, Z21


Patients who use hospice services any time during the measurement period: G9805


Patients who received cervical cytology or an HPV test during the measurement period

Numerator Instructions:

INVERSE MEASURE – A lower calculated performance rate for this measure indicates better clinical care or control. The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures, a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control.

Numerator Options:

Performance Met:

Patients who received cervical cytology or an HPV test (G9806)


Performance Not Met:

Patients who did not receive cervical cytology or an HPV test (G9807)


CMS-Family-Medicine-2022, CMS-Internal-Medicine-2022, CMS-Obstetrics-Gynecology-2022, General Practice/Family Medicine-2022, Internal Medicine-2022, Obstetrics/Gynecology-2022, Quality-2022, Telehealth-2022